Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.

De Oliveira, Gustavo Laine Araujo ORCID: 0000-0003-4811-7753, Guerra Júnior, Augusto Afonso ORCID: 0000-0001-5256-0577, Godman, Brian ORCID: 0000-0001-6539-6972 and Acurcio, Francisco de Assis ORCID: 0000-0002-5880-5261 (2017) Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications. Expert review of pharmacoeconomics & outcomes research, 17 (2). pp. 109-119.

Access the full-text of this item by clicking on the Open Access link.

Text CEA vildagliptin accepted for publication.docx - Author Accepted Manuscript Download (208kB)

Abstract

<h4>Introduction</h4>Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context. Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.

Item Type:	Article
Additional Information:	peerreview_statement: The publishing and review policy for this title is described in its Aims & Scope. aims_and_scope_url: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ierp20
Uncontrolled Keywords:	Humans, Diabetes Mellitus, Type 2, Metformin, Adamantane, Nitriles, Pyrrolidines, Hypoglycemic Agents, Drug Therapy, Combination, Models, Economic, Cost-Benefit Analysis, Brazil, Dipeptidyl-Peptidase IV Inhibitors, Vildagliptin
Depositing User:	Symplectic Admin
Date Deposited:	13 Jun 2017 06:39
Last Modified:	17 Mar 2024 13:45
DOI:	10.1080/14737167.2017.1292852
Open Access URL:	https://strathprints.strath.ac.uk/59774/1/de_Olive...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3007946